Home > Healthcare > Pharmaceuticals > Finished Drug Form > Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market Trends

Report ID: GMI6491
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Intravenous Immunoglobulin (IVIG) Market Trends

The market is undergoing transformation due to several influential trends that are shaping its trajectory of growth and advancement. Among the pivotal trends observed within this market are the increasing utilization of IVIG in the treatment of neurological disorders, the expansion of personalized medicine principles into IVIG therapy, the ascent of emerging immunomodulatory treatments, the transition from hospital-centric care to alternative healthcare settings affecting IVIG administration, and the surging demand coupled with concerns regarding supply chain stability.

Furthermore, the emergence of biosimilar variants of IVIG products has introduced a new dimension of competition to the market. This trend holds the potential to enhance accessibility to IVIG therapy while simultaneously impacting the dynamics of pricing. Additionally, breakthroughs in plasma collection technologies have been pivotal, aiming to enhance efficiency and yield in the extraction of high-quality plasma. These advancements are of paramount importance in ensuring a consistent supply of plasma for the production of IVIG. Collectively, these trends are poised to propel the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intravenous immunoglobulin (IVIG) industry size was USD 10.9 billion in 2022 and is projected to exhibit 7.6% CAGR from 2023 to 2032 attributed to the high prevalence of primary immunodeficiency disorders and secondary immunodeficiencies worldwide.

The IgG segment is poised to record significant growth through 2032 driven by its remarkable versatility, which encompasses a diverse array of functions within the immune system.

North America held 52.3% share of the IVIG market in 2022 and is anticipated to grow at 7.7% CAGR from 2023 to 2032 owing to the high prevalence of immune-mediated diseases, autoimmune disorders, and primary immunodeficiency diseases.

Some of the major companies in the intravenous immunoglobulin industry are Takeda Pharmaceutical Company Limited., Grifols SA, ADMA Biologics, Octapharma AG, Baxter International Inc., LFB Biotechnologies, China Biologics Products Inc., Kedrion Biopharma, and Intas Pharmaceuticals.